Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
BioSpace
The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
pharminent
July 27, 2026 (Last updated: July 27, 2026)
BioSpace
The star of the takeover is Forte Biosciences’ investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
